Clinical Trials Browser

Phase 2 × Interventional × Adjuvants, Pharmaceutic × Clear all

NCT06788912 2026-06-01

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

Phase 2 Active not recruiting

Breast Neoplasms

NCT02296684 2026-05-08

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

67 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06116578 2025-12-01

NeoSarc

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

NCT04727307 2025-09-30

AB-LATE02

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2 Terminated

120 enrolled 12 charts

Ovarian Neoplasms

NCT02576561 2017-10-25

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

Phase 2 Unknown

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00693615 2016-09-16

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Phase 2 Completed

Papillomavirus Infections